Doctor Rebecca Tay is the Founder and Chief Executive Officer of Global Precision Diagnostics, an award-winning, patient-centric, hospital-based pathology and clinical laboratory. She is also a winner of the Study UK Alumni Awards 2026 in the Business and Innovation category, recognised with the title “Pioneer of Entrepreneurship in Precision Medicine.

Losing her biological mother in her thirties to cancer, Dr. Rebecca has been devoted to becoming a medical scientist for leading-edge medical breakthroughs and healthcare solutions for human diseases. Driven by this devotion, she is grateful to be the first Dual PhD graduate from the University of Nottingham, UK in Pharmacy and University Putra Malaysia (UPM) in Molecular Medicine. She had successfully filed the patent for the discovery of novel molecular pathways associated with clinical outcome improvement.

She was overwhelmed by how advancement in Pharmacogenomics (PGx) could potentially integrate into cutting-edge healthcare to prevent adverse drug reactions (ADRs) when she was given opportunity at The University of Nottingham to teach Pharmacogenomics to the students under the problem-based learning (PBL) program. Geared up with the comprehension of precision medicine, using genetic profiling, she, her husband, and a team of healthcare providers were able to intervene and assist her stepmom in entering remission from her fourth-stage lung cancer. Seeing her stepmom living a quality life in her fifth year since diagnosis, motivated her to develop a cutting-edge diagnostic laboratory that is affordable to the nation.

Teaming up with renowned scientific healthcare policymakers and medical council, she is dedicated to translating scientific discovery into Medical Revolution in the preventative, diagnostic, and therapeutic healthcare industry, transitioning from the ‘One-drug-fits-all” paradigm towards personalised-tailored-treatment, namely Precision Medicine. She managed to acquire millions of investments or sponsorships from various local and Fortune 500 companies and successfully developed genome-wide Pharmacogenomic testing, namely PRECISE Pharmacogenomic. PRECISE Pharmacogenomic reporting is curated with medical databases accredited by UKAS (United Kingdom Accreditation Service) ISO 13845 for the Quality Management System certification NQA (National Quality Assurance Limited) and Health Sciences Authority (HSA), Republic of Singapore to support clinicians for clinical recommendation and personalised targeted treatment.